Chemotherapy-Induced Anemia Pipeline Insights Report, 2024 Featuring Analysis of Roxadustat (FibroGen), SPP-003 (SBI Pharmaceuticals), and More Dublin, May 31, 2024 (GLOBE NEWSWIRE) -- The "Chemotherapy-Induced Anemia - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference SAN FRANCISCO, March 26, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Thane Wettig, Chief Executive Officer, will participate in a corporate presentation at the 23rd...

FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019 SAN FRANCISCO, Nov. 04, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced that financial results for the third quarter 2019 will be released after market on Monday, November...

FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced first patient dosed in the company’s Phase 2 clinical study of roxadustat, a first-in-class...